An interventional study of CRIC and MFT in Hypertension, sponsored by Henan Institute of Cardiovascular Epidemiology. Completed at 5 sites in China. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-11-10.
Sponsored by Henan Institute of Cardiovascular Epidemiology · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 410 studies in Hypertension with a site in China — 124 open to participants now, 148 under way, 12 of them phase 3. Hypertension · China.
Among the 410 studies in Hypertension with a site in China, this one is the 67th largest by enrollment of the 308 interventional ones that give a count, is one of 29 that started in 2023, is one of 146 with no phase, and was the 199th registered.
6,128 studies on the registry are indexed under Hypertension; 907 are open to participants now.
Browse Hypertension studies →124 of the 410 studies in Hypertension with a site in China are open now. Recruiting first, the newest first:
Shandong Suncadia Medicine Co., Ltd. · Sites in China
Ages 18–80
Shanghai Jiao Tong University School of Medicine · Sites in China
Ages 18+
AstraZeneca · Sites in China
Ages 18+
Pulnovo Medical, Inc. · Sites in China, United States
Ages 18–85
China Medical University, China · Sites in China
Ages 50–75
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 552 Hypertension studies recruiting now, 260 (47%) set no upper age limit and 198 (36%) stop at 75 or younger; 40 take children under 18; 136 take healthy volunteers.
This study: 18 Years to 80 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
410 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 22 · Phase 2 23 · Phase 3 50 · Phase 4 76
First in 1998; this study’s year is marked. 29 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 600 is above the median of 100 across 4,585 interventional studies indexed under Hypertension.
Median enrollment 253 across the 308 interventional studies, 1,000 across the 102 observational. Of the 161 that completed or were terminated, 22 (14%) have results posted.
This tab as a report to print or save as PDF → With an account.
103 of 410 have an industry lead sponsor. The 10 most frequent:
Henan Institute of Cardiovascular Epidemiology is the lead sponsor of 31 studies on the registry; 11 are open to participants now.
Henan Institute of Cardiovascular Epidemiology has 3 studies filed under Hypertension — fewer than ten, so there is no comparison to draw.
47 of the studies in Hypertension with a site in China that are under way reach primary completion within a year, 4 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03683186Phase 3United TherapeuticsA Study Evaluating the Long-Term Efficacy and Safety of Ralinepag in Subjects With PAH Via an Open-Label Extension | 2026-12 |
| NCT06948422Phase 3Eli Lilly and CompanyA Master Protocol for Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight: (ATTAIN-Hypertension Screening) | 2027-09 |
| NCT06948435Phase 3Eli Lilly and CompanyA Master Protocol Study of Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight (ATTAIN-Hypertension) GZL1 | 2027-09 |
| NCT06952530Phase 3Eli Lilly and CompanyA Master Protocol Study of Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight (ATTAIN-Hypertension) GZL2 | 2027-09 |
| NCT07241338Jing LiuSacubitril/Allisartan for Hypertensive Patients With Overweight or Obesity | 2026-11 |
Add all 47 to your calendar (.ics) → With an account.
Among the 410 studies in Hypertension with a site in China, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Hypertension is a major risk factor for cardiovascular disease. Remote ischemic conditioning (RIC) and mindfulness-based interventions are non-pharmacological approaches that may help reduce blood pressure through different physiological mechanisms. However, evidence regarding their long-term effects and potential combined benefits remains limited.
This multicenter, randomized, sham-controlled clinical trial evaluated the effects of RIC, mindfulness-based intervention, and their combination on home blood pressure in patients with hypertension. A total of 600 participants were randomly assigned to four groups in a 2×2 factorial design. The interventions were administered twice daily for 12 months. The primary objective was to assess changes in home systolic blood pressure after 12 months of intervention. Secondary objectives included evaluating diastolic blood pressure, the time course of blood pressure changes, treatment response, and safety.
This was a multicenter, randomized, sham-controlled, 2×2 factorial clinical trial conducted at five hospitals in China. A total of 600 patients with essential hypertension were enrolled between September 2023 and August 2024 and randomly assigned in a 1:1:1:1 ratio to four intervention groups:
Active RIC consisted of three cycles of upper-arm cuff inflation for 6 minutes followed by deflation for 4 minutes, with a total session duration of 30 minutes. Inflation pressure was individualized according to baseline systolic blood pressure using predefined pressure increments. Sham RIC followed the same inflation-deflation schedule with a cuff pressure of 60 mmHg.
The mindfulness intervention consisted of standardized audio-guided mindfulness practice delivered simultaneously with the cuff intervention. The control audio consisted of natural sounds, such as ocean waves, flowing water, and birdsong, without hypertension education or mindfulness instructions. Both interventions were administered twice daily for 12 months.
Home blood pressure was measured repeatedly throughout the study using an automated monitoring system. The primary outcome was the change in pre-intervention home systolic blood pressure from baseline to 12 months. Additional assessments included diastolic blood pressure, longitudinal blood pressure trajectories, blood pressure control and response rates, immediate blood pressure responses, treatment adherence, and adverse events.
Selected circulating biomarkers were also measured in a subset of participants for mechanistic investigations.
The study was designed to assess the independent and combined effects of RIC and mindfulness-based intervention on long-term blood pressure control.
The criteria were revised on the registry on Nov 10, 2026. See what changed
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
LVEF (left ventricular ejection fraction)
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CRIC :Twice daily for 12 months using an automated cuff device. Each 30-minute session consisted of 3 cycles of 6 min inflation (pressure individualized: resting SBP-based increments of +40/+30/+20 mmHg depending on baseline SBP level) followed by 4 min deflation (0 mmHg). MFT:Twice daily guided audio sessions (synchronized with CRIC timing) emphasizing focused attention on breath and bodily sensations to foster mindful awareness.
Device: CRIC · Behavioral: MFT
Sham CRIC: Identical schedule and device; each cycle used fixed 5 min inflation at 60 mmHg (non-ischemic) followed by 5 min deflation. MFT: Twice daily guided audio sessions (synchronized with CRIC timing) emphasizing focused attention on breath and bodily sensations to foster mindful awareness.
Behavioral: MFT · Other: sham CRIC
CRIC :Twice daily for 12 months using an automated cuff device. Each 30-minute session consisted of 3 cycles of 6 min inflation (pressure individualized: resting SBP-based increments of +40/+30/+20 mmHg depending on baseline SBP level) followed by 4 min deflation (0 mmHg). Sham MFT: Twice daily equivalent-duration audio of looped neutral nature sounds (ocean waves, flowing water, birdsong) without mindfulness instructions.
Device: CRIC · Other: sham MFT
Sham CRIC: Identical schedule and device; each cycle used fixed 5 min inflation at 60 mmHg (non-ischemic) followed by 5 min deflation. Sham MFT: Twice daily equivalent-duration audio of looped neutral nature sounds (ocean waves, flowing water, birdsong) without mindfulness instructions.
Other: sham CRIC · Other: sham MFT
Remote Ischemic Conditioning (CRIC): Twice daily for 12 months using an automated cuff device. Each 30-minute session consisted of 3 cycles of 6 min inflation (pressure individualized: resting SBP-based increments of +40/+30/+20 mmHg depending on baseline SBP level) followed by 4 min deflation (0 mmHg).
Mindfulness-based intervention (MFT) consisted of standardized audio-guided mindfulness practice focusing on breath awareness, bodily sensations, and nonjudgmental present-moment awareness. Each session lasted approximately 30 minutes and was delivered twice daily for 12 months, synchronized with the CRIC or sham CRIC procedure.
Mindfulness-based intervention (MFT) consisted of standardized audio-guided mindfulness practice focusing on breath awareness, bodily sensations, and nonjudgmental present-moment awareness. Each session lasted approximately 30 minutes and was delivered twice daily for 12 months, synchronized with the CRIC or sham CRIC procedure.
The control audio consisted of standardized recordings of natural sounds, including ocean waves, flowing water, and birdsong, without mindfulness instructions, breathing exercises, or hypertension-related health education. Each audio session lasted approximately 30 minutes and was delivered twice daily for 12 months, synchronized with the CRIC or sham CRIC procedure.
Change From Baseline in Home Systolic Blood Pressure at 12 Months
Change in mean pre-intervention home systolic blood pressure (SBP) from screening baseline to the 12-month endpoint window. Home blood pressure was measured twice daily using an automated device. Three measurements were obtained before each intervention session; the first reading was excluded, and the mean of the remaining two readings was used. The 12-month endpoint was calculated as the mean of valid pre-intervention SBP measurements during days 335-364 after randomization. Participants with at least 20 valid measurement sessions during this window were included in the primary endpoint analysis. The outcome was expressed in mmHg.
Time frame: Baseline (screening days -7 to -1) and Month 12 (days 335-364 after randomization)
Change From Baseline in Home Diastolic Blood Pressure at 12 Months
Change in mean pre-intervention home diastolic blood pressure (DBP) from screening baseline to the 12-month endpoint window. Home blood pressure was measured twice daily using an automated device. Three measurements were obtained before each intervention session; the first reading was discarded, and the mean of the remaining two readings was used. The 12-month endpoint was calculated as the mean of valid pre-intervention DBP measurements during days 335-364 after randomization. Changes were expressed in mmHg.
Time frame: Baseline (screening days -7 to -1) and Month 12 (days 335-364)
Change From Baseline in Home Systolic Blood Pressure at Months 1, 3, 6, and 9
Changes in mean pre-intervention home systolic blood pressure (SBP) from screening baseline at multiple follow-up time points. Home SBP was measured twice daily using an automated device, with the mean of the second and third pre-intervention readings used for each session. Window-mean SBP values were calculated around days 30, 90, 180, and 270 after randomization to characterize the longitudinal blood pressure response to the assigned interventions. Changes were expressed in mmHg.
Time frame: Baseline and Days 30, 90, 180, and 270 after randomization
Proportion of Participants Achieving a Systolic Blood Pressure Reduction of at Least 5 mmHg
Proportion of participants achieving a reduction of at least 5 mmHg in mean pre-intervention home systolic blood pressure from screening baseline to the 12-month endpoint window (days 335-364 after randomization). The response rate was calculated as the number of participants meeting this threshold divided by the number of participants with evaluable endpoint data, expressed as a percentage.
Time frame: Baseline and Month 12 (days 335-364)
Proportion of Participants Achieving Home Blood Pressure Control Below 135/85 mmHg
Proportion of participants achieving home blood pressure control, defined as a mean pre-intervention home systolic blood pressure below 135 mmHg and a mean pre-intervention home diastolic blood pressure below 85 mmHg during the 12-month endpoint window (days 335-364 after randomization). Blood pressure control rates were expressed as percentages among participants with evaluable endpoint data.
Time frame: Month 12 (days 335-364)
Proportion of Participants Achieving Home Blood Pressure Control Below 140/90 mmHg
Proportion of participants achieving home blood pressure control using a less stringent threshold, defined as a mean pre-intervention home systolic blood pressure below 140 mmHg and a mean pre-intervention home diastolic blood pressure below 90 mmHg during the 12-month endpoint window (days 335-364 after randomization). Blood pressure control rates were expressed as percentages among participants with evaluable endpoint data.
Time frame: Month 12 (days 335-364)
Within-Session Change in Home Systolic Blood Pressure
The immediate blood pressure response was assessed as the difference between post-intervention and pre-intervention home systolic blood pressure within each treatment session. Three consecutive blood pressure measurements were obtained before and after each session, with the first reading excluded and the mean of the remaining two readings used for each time point. The participant-level mean of post-intervention minus pre-intervention SBP differences was calculated across available sessions. Between-group comparisons relative to the double-sham control group were used to estimate the net immediate intervention effect, expressed in mmHg.
Time frame: Throughout the 12-month intervention period
Plan to share: No — IPD can be obtained from the researcher upon reasonable request
Ran from Sep 2023 to primary completion in Aug 2025, 23 months.
Of 1,407 non-industry interventional studies with no phase under Hypertension, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 41. This study's 23 months is close to that.
Counting every sponsor, half of 1,502 studies reached it within 23 months; a quarter within 10 and three quarters within 42.
Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 10, 2026: start Jul 2021 → Sep 2023, primary completion Dec 2026 → Aug 2025 and completion Dec 2030 → Jan 2026.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Henan Institute of Cardiovascular Epidemiology